PHARMACOKINETICS AND BIOAVAILABILITY OF FLUCLOXACILLIN IN ELDERLY HOSPITALIZED-PATIENTS

被引:22
作者
GATH, J
CHARLES, B
SAMPSON, J
SMITHURST, B
机构
[1] UNIV QUEENSLAND,DEPT PHARM,BRISBANE,QLD 4072,AUSTRALIA
[2] UNIV QUEENSLAND,DEPT SOCIAL & PREVENT MED,BRISBANE,QLD 4072,AUSTRALIA
[3] QUEEN ELIZABETH II JUBILEE HOSP,BRISBANE,QLD,AUSTRALIA
[4] MT OLIVET HOSP,BRISBANE,QLD,AUSTRALIA
关键词
D O I
10.1002/j.1552-4604.1995.tb04742.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics and oral bioavailability of flucloxacillin were studied in five female and two male patients (age 68-87 yr) who had been hospitalized for orthopedic surgeries. A single dose of intravenous or oral flucloxacillin sodium (500 mg) was administered in random order on different occasions separated by at least 2 days. Blood and urine samples were taken up to 24 hours after drug administration and levels of flucloxacillin and 5-hydroxymethylfluclozacillin (5-HMF), a major metabolite, were measured by high-performance liquid chromatography. Fluclozacillin elimination, but not oral absorption, was reduced in the elderly, compared with data from young healthy subjects reported elsewhere. Total clearance, renal clearance, and volume of distribution were 0.083+/-0.013 L/kg/hr, 0.038+/-0.01 L/kg/hr, and 0.184+/-0.034 L/kg, respectively. Regression of flucloxacillin renal clearance (Cl-r) on estimated creatinine clearance (CL(cr)) gave the relationship: Cl-r = 0.755 (CL(cr)) + 10.6 (r = 0.91; P = 0.004). Terminal half-lives for flucloxacillin and 5-HMF were 2.21+/-0.51 hr and 3.0+/-0.75 hr, respectively, after intravenous administration. Flucloxacillin was absorbed rapidly after oral administration, with a mean absorption time of 0.95+/-0.34 hr, and time to reach peak concentration of 1.20+/-0.29 hr. The absolute bioavailability of flucloxacillin from capsules was 54.4+/-18.8%.
引用
收藏
页码:31 / 36
页数:6
相关论文
共 27 条
[1]   PHARMACOKINETICS AND DISTRIBUTION OF FLUCLOXACILLIN IN PACEMAKER PATIENTS [J].
ANDERSON, P ;
BLUHM, G ;
EHRNEBO, M ;
HERNGREN, L ;
JACOBSON, B .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 27 (06) :713-719
[2]   CROSSOVER STUDY OF PENICILLIN PHARMACOKINETICS AFTER INTRAVENOUS INFUSIONS [J].
BERGAN, T ;
OYDVIN, B .
CHEMOTHERAPY, 1974, 20 (05) :263-279
[3]  
BERGDAHL S, 1986, ACTA PHARMACOL TOX, V58, P255
[4]  
BODEY GP, 1972, CLIN PHARMACOL THER, V13, P512
[5]   ADAPTIVE COMPUTER-PROGRAM FOR DETERMINATION OF ABSORPTION PROFILES BY NUMERICAL DECONVOLUTION - APPLICATION TO AMOXICILLIN ABSORPTION [J].
DESLANDES, A ;
WESTPHAL, JF ;
TROUVIN, JH ;
FARINOTTI, R .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (08) :802-807
[7]   FLUCLOXACILLIN JAUNDICE [J].
FAIRLEY, CK ;
BOYD, I ;
PURCELL, P ;
MCNEIL, J .
LANCET, 1992, 339 (8794) :679-679
[8]   RELATIONSHIP BETWEEN PENICILLINASE PRODUCTION AND THE INVITRO ACTIVITY OF METHICILLIN, OXACILLIN, CLOXACILLIN, DICLOXACILLIN, FLUCLOXACILLIN, AND CEPHALOTHIN AGAINST STRAINS OF STAPHYLOCOCCUS-AUREUS OF DIFFERENT PHAGE PATTERNS AND PENICILLINASE ACTIVITY [J].
FRIMODTMOLLER, N ;
ROSDAHL, VT ;
SORENSEN, G ;
HARTZEN, SH ;
BENTZON, MW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1986, 18 (01) :27-33
[9]   DICLOXACILLIN AND FLUCLOXACILLIN TWICE DAILY WITH PROBENECID IN STAPHYLOCOCCAL INFECTIONS - A CLINICAL AND PHARMACOKINETIC EVALUATION [J].
HEDSTROM, SA ;
KAHLMETER, G .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1980, 12 (03) :221-225
[10]   PHARMACOKINETICS OF FREE AND TOTAL FLUCLOXACILIN IN NEWBORN-INFANTS [J].
HERNGREN, L ;
EHRNEBO, M ;
BROBERGER, U .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 32 (04) :403-409